CHRISTOPHER ESPELIN,ELENA GERETTI,VICTOR MOYO,JOSEPH G. REYNOLDS,THOMAS WICKHAM,BART S. HENDRIKS
申请号：
US15369094
公开号：
US20170080087A1
申请日:
2016.12.05
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
